Hosted on MSN6d
Omnicell (NASDAQ:OMCL) Exceeds Q4 Expectations But Full-Year Sales Guidance Misses ExpectationsHealthcare tech company Omnicell (NASDAQ:OMCL) reported Q4 CY2024 results , with sales up 18.6% year on year to $306.9 ...
Benchmark analysts maintained a Buy rating on Omnicell stock (NASDAQ:OMCL) with a consistent price target of $62.00 as the company approaches its earnings release scheduled for February 6. The target ...
Here at Omnicell, we are entering 2025 with a renewed ... Thanks, Allen, for the questions. Yes, I think the hospital financial conditions and providers have continued to improve.
Omnicell reported Q4 2024 revenues of $307 ... Allen Lutz, Bank of America: Asked about hospital budget growth and product revenue ramp. CEO Lipps responded, "Improved financial conditions of ...
OMNICELL ($OMCL) posted quarterly earnings results on Thursday, February 6th. The company reported earnings of $0.60 per share, beating estimates of $0.59 by $0.01 ...
It's been a mediocre week for Omnicell, Inc. (NASDAQ:OMCL) shareholders, with the stock dropping 11% to US$40.16 in the week since its latest annual results. Revenues were US$1.1b, approximately ...
For the current quarter ending in March, Omnicell expects its per-share earnings to range from 15 cents to 25 cents. The company said it expects revenue in the range of $255 million to $265 ...
Healthcare tech company Omnicell (NASDAQ:OMCL ... However, headwinds such as tightening hospital budgets, cybersecurity threats, and the fragmented nature of healthcare systems could slow adoption.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results